Inovio Pharmaceuticals/$INO
1D1W1MYTD1Y5YMAX
Capital at risk
About Inovio Pharmaceuticals
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
- Ticker
- $INO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 112
- Headquarters
- Plymouth Meeting, United States
- Website
- www.inovio.com
INO Metrics
BasicAdvanced
$128M
-
-$1.03
1.51
-
Price and volume
Market cap
$128M
Beta
1.51
52-week high
$2.72
52-week low
$0.56
Average daily volume
4.2M
Financial strength
Current ratio
1
Quick ratio
0.919
Long term debt to equity
1.168
Total debt to equity
1.831
Profitability
EBITDA (TTM)
-77.932
Management effectiveness
Return on assets (TTM)
-84.23%
Return on equity (TTM)
-409.87%
Valuation
Price to book
23.36
Price to tangible book (TTM)
23.36
Price to free cash flow (TTM)
-1.001
Free cash flow yield (TTM)
-99.88%
Free cash flow per share (TTM)
-1.238
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-60.07%
3-year earnings per share growth (CAGR)
-49.24%
10-year earnings per share growth (CAGR)
-16.86%
What the Analysts think about INO
Analyst ratings (Buy, Hold, Sell) for Inovio Pharmaceuticals stock.
Analyst projections of the future price of Inovio Pharmaceuticals stock.
INO Financial Performance
Revenues and expenses
INO Earnings Performance
Company profitability
Upcoming events
No upcoming events
INO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.